Fenwick represented Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, in its up-sized $175 million Series B financing.
Proceeds from the financing will be used to advance Metagenomi’s lead in vivo and ex vivo gene editing therapeutic programs through preclinical development and into the clinic. The round was led by PFM Health Sciences, Farallon Capital Management and a global investment firm. More information about the financing and additional investors can be obtained from Metagenomi’s announcement.
The Fenwick transaction team included corporate partners Matthew Rossiter and Jonathan Sagot and associates Joon Hwan Kim, Kristen Nicol and Elizabeth Gil.